Bringing this interview with Marla Black Morgan, MD, to a close, she looks to the future of research in both myasthenia ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and ...

Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States solely dedicated to the myasthenia gravis (MG) community, announced the ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis ...

YANTAI, China, May 27, 2025 /PRNewswire/ -- On May 27, RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National ...

The new drug joins UCB’s recently FDA-approved FcRn-targeting antibody Rystiggo (rozanolixizumab), which got the nod from the US regulator in June for gMG patients who are either AChR or anti ...

Cartesian Therapeutics enrolls first participant in Phase 3 trial of Descartes-08 for myasthenia gravis treatment. Quiver AI Summary. Cartesian Therapeutics, Inc. has announced the enrollment of ...

Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.. Last reviewed: 04 June 2025 Next review: This guidance will be ...

Myasthenia gravis with hyperthyroidism and exophthalmic goiter has been reported. Eaton is quoted by McEachern and Parnell 2 as stating that 6 per cent of myasthenic patients studied at the Mayo ...

1 Department of Clinical Medicine, University of Bergen, Bergen, Norway. 2 Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway NE Gilhus has received honorarium for ...

Myasthenia gravis (MG) should be classified according to antibody status (acetylcholine, MuSK, LRP4, titin), thymus (hyperplasia, neoplasia, atrophy), age at debut (< or >50 years), symptom ...